Correction: Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect Free

In this article (Mol Cancer Ther 2013;12:1816–28), which appeared in the September 2013 issue of Molecular Cancer Therapeutics (1), the authors regret that the article title was incorrect.

The authors forgot to mention the company code of HER2-targeted liposomal doxorubicin (MM-302) for reference. The company code is important for other investigators to link this work with other ongoing clinical trials that are using MM-302. The publisher recommended that correcting the title was the most appropriate means for making this link. The correct title is given below.

“Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin (MM-302)-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect”.